Showing 2041-2050 of 2652 results for "".
- B+L Shares Dry Eye Survey Results and Launches Awareness Campaignhttps://modernod.com/news/bl-shares-dry-eye-survey-results-and-launches-awareness-campaign/2482346/Bausch + Lomb shared results from its 'State of Dry Eye' survey, which aimed to explore dry eye understanding and experiences among adults in the US. The research was conducted online by The Harris Poll on behalf of Bausch + Lomb among 2,003 U.S. adults 18 years o
- PharmAbcine Advances Phase 1 Clinical Trial of PMC-403 for nAMDhttps://modernod.com/news/pharmabcine-advances-phase-1-clinical-trial-of-pmc-403-for-namd/2482343/PharmAbcine, Inc., a South Korea-based clinical-stage developer of medical therapeutics, announced the Safety Review Committee (SRC) approval of single 3-mg dose for the third cohort in phase 1 clinical trial of PMC-403, the company&rsquo
- FDA Approves Genentech’s Vabysmo Prefilled Syringe for AMD, DME, and RVOhttps://modernod.com/news/genentechs-vabysmo-prefilled-syringe-approved-by-fda-for-amd-dme-and-rvo/2482342/Genentech announced FDA approval of Vabysmo (faricimab-svoa) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema after retinal vein occlusion (RVO). The company advised that Vabysmo
- Karen Petrou Appointed Board Chair of the Foundation Fighting Blindnesshttps://modernod.com/news/karen-petrou-appointed-board-chair-of-the-foundation-fighting-blindness/2482334/The Foundation Fighting Blindness announced the appointment of Karen Petrou as Board Chair, effective July 1, 2024. Petrou succeeds David Brint, who is retiring after 8 years of service. Ms. Petrou’s becomes the third person to hold the position in the Foundation&rs
- 2024 Kavli Prize in Neuroscience Awarded for the Discovery of 'Face Areas' in the Brainhttps://modernod.com/news/2024-kavli-prize-in-neuroscience-awarded-for-the-discovery-of-face-areas-in-the-brain/2482322/The 2024 Kavli Prize in Neuroscience honors Nancy Kanwisher, PhD, (Massachusetts Institute of Technology); Doris Ying Tsao, PhD (University of California, Berkeley); and Winrich Freiwald, Ph.D. (Rockefeller University) for the discovery of a specialized system within the brain to r
- Eversight Partners with LighTopTech to Improve Imaging Modalities for Eye Tissueshttps://modernod.com/news/eversight-partners-with-lightoptech-to-improve-imaging-modalities-for-eye-tissues/2482310/Eversight announced a 4-year partnership with LighTopTech that aims to improve imaging modalities for eye tissues in both clinical and research settings. Financial terms of the deal were not disclosed. As part of th
- Researchers Detail How Neurons Build a 3-D Vascular Structure to Keep the Retina Healthyhttps://modernod.com/news/researchers-detail-how-neurons-build-a-3-d-vascular-structure-to-keep-the-retina-healthy/2482292/Scientists have known for years that a lattice of blood vessels nourishes cells in the retina that allow us to see – but it’s been a mystery how the intricate structure is created. Now, researchers at University of California San Francisco have found a new type of neuron that guides i
- FDA Approves First Interchangeable Biosimilars to Eyleahttps://modernod.com/news/fda-approves-first-interchangeable-biosimilars-to-eylea/2482286/The FDA has approved Biocon’s Yesafili (aflibercept-jbvf) and Samsung Bioepis and Biogen’s Opuviz (aflibercept-yszy) as the first interchangeable biosimilars to Eylea (aflibercept). Yesafili and Opuviz are used to treat wet age-related macular degeneratio
- New Research Reveals COVID-19 Virus Could Damage Visionhttps://modernod.com/news/new-research-reveals-covid-19-virus-could-damage-vision/2482285/Researchers at the University of Missouri School of Medicine have discovered the virus that causes COVID-19 can breach the blood-retinal barrier with potential long-term consequences in the eye. Using a humanized ACE2 mice model, research led by Pawan Kumar Singh, PhD, an assi
- RevOpsis Names Emmett Cunningham, MD, PhD, to Strategic Advisory Boardhttps://modernod.com/news/revopsis-names-emmett-cunningham-md-phd-to-strategic-advisory-board/2482273/RevOpsis Therapeutics announced the appointment of Emmett Cunningham, MD, PhD, to its Strategic Advisory Board (SAB) and as a private investor. Dr. Cunningham brings more than 20 years of experience as a full-time entrepreneur and investor to his new role with RevOpsis. Dr. Cunning